DJIA 17,630.27 189.68 1.09%
NASDAQ 5,089.21 0.00 0.00%
S&P 500 2,093.25 25.61 1.24%
market minute promo

3.61 0.02 (0.56%)

REAL-TIME: Last trade at

Extended Hours: $3.57 -$0.04 (-1.11%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

IDRA $3.61 0.56%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.60
Previous Close $3.59
Daily Range $3.51 - $3.70
52-Week Range $1.94 - $5.48
Market Cap $425.5M
P/E Ratio -7.64
Dividend (Yield) $0.00 (0.0%)
Volume 1,353,415
Average Daily Volume 1,774,566
Current FY EPS -$0.46

Sector

Healthcare

Industry

Drug Makers

Idera Pharmaceuticals, Inc. (IDRA) Description

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants. Website: http://www.iderapharma.com/

News & Commentary Rss Feed

Why Idera Pharmaceuticals Inc. Shares Vaulted Higher

Idera Pharmaceuticals' stock rockets higher after announcing fresh data on one of its clinical compounds -- but should you be buying?

Idera Pharmaceuticals (IDRA) in Focus: Stock Jumps 5.3% - Tale of the Tape

Idera Pharmaceuticals (IDRA) Flagged As Strong On High Volume

Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: June 21 - 27

Idera Pharmaceuticals Announces Appointment of Mark J. Casey as General Counsel and Secretary of the

Idera Pharmaceuticals Announces Appointment of Mark J. Casey as General Counsel and Secretary of the Board of Directors

Mid-Afternoon Market Update: Standard Pacific Rises On Ryland Merger Deal; Micron Shares Slip

Mid-Day Market Update: DealerTrack Jumps On Acquisition News; AirMedia Shares Decline

Idera Phamaceuticals (IDRA) Stock Jumping Following New Coverage

Analysts Actions -- EMC, Micron, SanDisk and More

Idera Pharmaceuticals Enters Into a Strategic Clinical Research Alliance With MD Anderson Cancer Cen

Idera Pharmaceuticals Enters Into a Strategic Clinical Research Alliance With MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination With Checkpoint Inhibitors

Idera Pharmaceuticals (IDRA) Weak On High Volume Today

See More IDRA News...

IDRA's Top Competitors

IDRA $3.61 (0.56%)
Current stock: IDRA
AMGN $172.74 (4.35%)
Current stock: AMGN
GILD $113.07 (2.29%)
Current stock: GILD
BIIB $319.93 (3.39%)
Current stock: BIIB